PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-12.41%
Revenue decline while AGEN shows 2257.45% growth. Joel Greenblatt would examine competitive position erosion.
No Data
No Data available this quarter, please select a different quarter.
-12.41%
Gross profit decline while AGEN shows 690.21% growth. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
29.66%
R&D growth less than half of AGEN's 13892.15%. David Dodd would verify if efficiency advantage is sustainable.
16.61%
G&A growth 50-75% of AGEN's 28.44%. Bruce Berkowitz would examine operational efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.48%
Similar operating expenses growth to AGEN's 28.44%. Walter Schloss would investigate norms.
25.48%
Total costs growth above 1.5x AGEN's 3.68%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
3.10%
D&A growth while AGEN reduces D&A. John Neff would investigate differences.
-28.10%
EBITDA decline while AGEN shows 388.90% growth. Joel Greenblatt would examine position.
-46.25%
EBITDA margin decline while AGEN shows 112.25% growth. Joel Greenblatt would examine position.
-27.47%
Operating income decline while AGEN shows 382.46% growth. Joel Greenblatt would examine position.
-45.52%
Operating margin decline while AGEN shows 111.98% growth. Joel Greenblatt would examine position.
-14.81%
Other expenses reduction while AGEN shows 41.67% growth. Joel Greenblatt would examine advantage.
-27.92%
Pre-tax income decline while AGEN shows 311.07% growth. Joel Greenblatt would examine position.
-46.04%
Pre-tax margin decline while AGEN shows 108.95% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-27.92%
Net income decline while AGEN shows 314.37% growth. Joel Greenblatt would examine position.
-46.04%
Net margin decline while AGEN shows 109.09% growth. Joel Greenblatt would examine position.
-20.00%
EPS decline while AGEN shows 303.08% growth. Joel Greenblatt would examine position.
-20.00%
Diluted EPS decline while AGEN shows 292.77% growth. Joel Greenblatt would examine position.
6.47%
Share count reduction below 50% of AGEN's 11.22%. Michael Burry would check for concerns.
6.47%
Diluted share reduction below 50% of AGEN's 10.69%. Michael Burry would check for concerns.